Thalidomide effects in COVID-19

A clinical trial to evaluate the therapeutic effects of thalidomide in patients with COVID-19 infection

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110423006257N3

Enrollment

Registered

2021-04-03

Start date

2021-04-09

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19. Covid 19

Interventions

Intervention 1: Intervention group: In this group, in addition to the standard drugs recommended in the protocol of the Ministry of Health and supportive measures for patients, thalidomide (Lipomed-Sw

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Duration of the symptoms less than 10 days Lymphocyte count less than 1000 per microliter Quantitative CRP more than 1.5 times normal Positive pcr test of covid 19 O2 sat less than 93% Respiratory rate less than 24 Chest CT scan findings compatible with COVID-19 Pneumonia

Exclusion criteria

Exclusion criteria: History of chronic disease Pregnant women, lactating women , sexually active premenopausal women Loss of consciousness Liver enzymes more than 5 times normal

Design outcomes

Primary

Measure	Time frame
Radiological changes of the lung. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Pulmonary computed topography scan.;Death rate. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: observation.;Length of hospitalization. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: observation.;Blood oxygen saturation. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Pulseoxymeter.	—

Measure

Time frame

Radiological changes of the lung. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Pulmonary computed topography scan.;Death rate. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: observation.;Length of hospitalization. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: observation.;Blood oxygen saturation. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Pulseoxymeter.

—

Secondary

Measure	Time frame
Complete blood count. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.;Erythrocyte sedimentation rate. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.;Interleukin 6. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.;Creatine phosphokinase. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.	—

Measure

Time frame

Complete blood count. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.;Erythrocyte sedimentation rate. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.;Interleukin 6. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.;Creatine phosphokinase. Timepoint: Before the intervention and two weeks after the intervention. Method of measurement: Paraclinical.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Abdollatif Moini

Arak University of Medical Sciences

dr.moini@arakmu.ac.ir+98 86 1222 5202

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026